Corticotropin-releasing factor1 receptor as a target for therapeutic intervention

Drugs of the Future

Volumn 24, Issue 10, 1999, Pages 1089-1098

  Nakazato, Atsuro ^a   Okuyama, Shigeru ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; MESSENGER RNA; NBI 30545; NBI 31200; PD 171729; RECEPTOR SUBTYPE; SA 241; SA 627; SC 241; SJ 948; SP 904; UNCLASSIFIED DRUG; XQ 771;

BRAIN; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032750541     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.10.665576     Document Type: Review

References (82)

1. Vale, W., Spiess, J., Rivier, C. et al. Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta endorphin. Science 1981, 213: 1394-7.
2. Dunn, A.J., Berridge, C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety of stress responses? Brain Res Rev 1990, 15: 71-100.
3. Owens, M.J., Nemeroff, C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991, 43: 425-73.
4. Britton, K.T., Lee, G., Dana, R. et al. Activating and anxiogenic effects of corticotropin-releasing factor are not inhibited by blockage of the pituitary-adrenal system with dexamethasone. Life Sci 1986, 39: 1281-6.
5. Britton, K.T., Lee, G., Vale, W. et al. Corticotropin-releasing factor (CRF) receptor antagonist blocks activating and anxiogenic actions of CRF in the rat. Brain Res 1986, 369: 303-6.
6. Buwalda, S., De Boer, S.F., Van Kalkeren, A.A. et al. Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology 1977, 22: 297-309.
7. Sarnyai, Z., Biro, E., Gardi, J. et al. Brain corticotropin-releasing factor mediates anxiety-like behaviour induced by cocaine withdrawal in rats. Brain Res 1995, 675: 89-95.
8. Skutella, T., Montkowski, A., Stohr, T. et al. Corticotropin-releasing hormone (CRF) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol Neurobiol 1994, 14: 579-88.
9. Levine, A.S., Rogers, B., Kneip, J. et al. Effect of centrally administered corticotropin-releasing factor (CRF) on multiple feeding paradigms. Neuropharmacology 1983, 22: 337-9.
10. Sirinathsinghji, D.J.S., Rees, L.H., Rivier, J.H. et al. Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat. Nature 1983, 305: 232-5.
11. Ehlers, C., Henriksen, S., Wang, M. et al. Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res 1983, 278: 332-6.
12. Nemeroff, C.B., Widerlov, E., Bissette, G. et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunore-activity in depressed patients. Science 1984, 226: 1342-4.
13. Darnell, A., Bremner, J.D., Licinio, J. et al. CSF levels of corticotropin-releasing factor in chronic post-traumatic stress disorder. Soc Neurosci Abst 1994, 20: 17.
14. Holsboer, F., Von Bardeleben, U., Gerken, A. et al. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. New Engl J Med 1984, 311:1127.
15. Taylor, A.L., Fishman, L.M. Corticotropin-releasing hormone. New Engl J Med 1988, 319: 213-22.
16. Rivier, J., Rivier, C., Vale, W. Synthetic competitive antagonists of corticotropin-releasing factor: Effects on ACTH secretion in the rat. Science 1984, 224: 889-91.
17. 1 receptor mRNA expression. J Neurosci 1995, 15: 6340-50.
18. Lovenberg, T.W, Liaw, C.W, Grigoriadis, D.E. et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995, 92: 836-40.
19. Mansi, J.A., Rivest, S., Drolet, G. Regulation of corticotropin-releasing factor type 1 (CRF) receptor messenger ribonucleic acid in the paraventricular nucleus of rat hypothalamus by exogenous CRF. Endocrinology 1996, 137: 4619-26.
20. 2 binding sites in adult rat brain. Neuropsychopharmacology 1997, 17: 308-16.
21. 2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995, 136: 4139-42.
22. Luo, Y., Kiss, A., Makara, G. et al. Stress-specific regulation of corticotropin-releasing hormone receptor expression in the paraventricular and supraoptic nuclei of the hypothalamus in the rat. J Neuroendocrinol 1994, 6: 689-96.
23. Rivest, S., Laflamme, N., Nappi, R.E. Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci 1995, 15: 2680-95.
24. Makino, S., Schulkin, J., Smith, M.A. et al. Regulation of corticotropin-releasing hormone receptor messenger ribonucleic acid in the rat brain and pituitary by glucocorticoids and stress. Endocrinology 1995, 136: 4517-25.
25. Makino, S., Takemura, T., Asaba, K. et al. Differential regulation of type-1 and type-2α corticotropin-releasing hormone receptor mRNA in the hypothalamic paraventricular nucleus of the rat. Mol Brain Res 1997, 47: 170-6.
26. 2' receptors mediate anxiogenic-like behavior. Regul Pept 1997, 71: 15-21.
27. Heinrichs, S.C., Merlo-Pich, E., Miczek, K.A. et al. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 1992, 581: 190-7.
28. Morimoto, A., Nakamori, T., Moromoto, K. et al. The central role of corticotropin-releasing factor (CRF1-41) in psychological stress in rats. J Physiol 1993, 460: 221-9.
29. Menzaghi, F., Howard, R.L., Heinrichs, S.C. et al. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 1994, 269: 564-72.
30. Kornreich, W.D., Galyean, R., Hernández, J-F. et al. Alanine series of ovine corticotropin-releasing factor (oCRF): A structure-activity relationship study. J Med Chem 1992, 35: 1870-6.
31. Rivier, J., Rivier, C., Galyean, R. et al. Single point D-substituted corticotropin-releasing factor analogues: Effects on potency and physicochemical characteristics. J Med Chem 1993, 36: 2851-9.
32. Hernández, J-F., Korneich, W., Rivier, C. et al. Synthesis and relative potencies of new constrained CRF antagonists. J Med Chem 1993, 36: 2860-7.
33. Miranda, A., Koerber, S.C., Gulyas, J. et al. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. J Med Chem 1994, 37: 1450-9.
34. Gulyas, J., Rivier, C., Perrin, M. et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor (CRF). Proc Natl Acad Sci USA 1995, 92: 10575-9.
35. Beyermann, M., Fechner, K., Furkert, J. et al. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin-releasing factor. J Med Chem 1996, 39: 3324-30.
36. Miranda, A., Lahrichi, S.L., Gulyas, J. et al. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges. J Med Chem 1997, 40: 3651-8.
37. River, J., Lahrichi, S.L., Gulyas, J. et al. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i + 3) Glu-Lys and Lys-Glu bridges. J Med Chem 1998, 41: 2614-20.
38. Koerber, S.C., Gulyas J., Lahrichi, S.L. et al. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i + 3) Glu-Xaa-DXbb-Lys bridges. J Med Chem 1998, 41: 5002-11.
39. Courtemanche, G., Gautier, C., Gully, D. et al. New 2-disubstitued amino-4-arylthiazole derivatives used for treating corticotropic hormone releasing factor. EP 576350.
40. Faraci, W.S., Welch, W.M. Pyrazoles and pyrazolopyrimidines having corticotropin-releasing factor antagonist activity. WO 9413643.
41. Whitten, J.P., Xie, Y.F., Erickson, P.E. et al. Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: Application to the synthesis and optimization of corticotropin-releasing factor 1 receptor antagonists. J Med Chem 1996, 39: 4354-7.
42. Chen, C., Dagnino, R., De Souza, E.B. et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor 1 receptor antagonists. J Med Chem 1996, 39: 4358-60.
43. 1 receptors in restraint-, CRF-, and urocortin-induced anxiety-like behaviors. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 470.15.
44. 1 receptor mediates the excitatory action of corticotropin releasing factor (CRF) in the developing rat brain: In vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res 1997, 770: 89-95.
45. 1) antagonists. 215th ACS Natl Meet (March 29-April 2, Dallas) 1998, Abst MEDI 141.
46. 1 receptor antagonists. 216th ACS Natl Meet (Aug 23-27, Boston) 1998, Abst MEDI 137.
47. 1 receptor antagonists, CRA1000 and CRA1001. Eur J Pharmacol 1999, 371: 205-11.
48. Okuyama, S., Chaki, S., Kawashima, N. et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 1999, 289: 926-35.
49. Aral, K., Ohata, H., Shibasaki, T. Non-peptidic corticotropin-releasing hormone receptor type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: Evidence that an increase in arousal induced by stress is mediated through CRH receptor type 1. Neurosci Lett 1998, 255: 103-6.
50. Hotta, M., Shibasaki, T., Arai, K. et al. Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. Brain Res 1999, 823: 221-5.
51. Arvanitis, A.G., Gilligan, P.J., Chorvat, R.J. et al. Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J Med Chem 1999, 42: 805-18.
52. Chen, Y.L., Mansbach, R.S., Winter, S.M. et al. Synthesis and oral efficacy of 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: A centrally active corticotropin-releasing factor 1 receptor antagonist. J Med Chem 1997, 40: 1749-54.
53. 1 receptor antagonist in the separation-induced vocalization model of anxiety in rat pups. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 82.5.
54. 1 receptor antagonist on shock-elicited startle, a novel model for assessing antistress activity of compounds. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 82.3.
55. 1 receptor antagonist in the Porsolt forced swim task, a model of depression. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 82.4.
56. Lee, Y., Terwilliger, R.Z., Duman, R.S. Regulation of corticotropin releasing factor receptor-1 (CRF-R1) and BDNF by morphine withdrawal. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 582.13.
57. Arborelius, L., Thrivikraman, K.V., Plotsky, P.M. Chronic treatment with the CRF receptor antagonist CP-154,526 decreases defensive withdrawal but does not alter neuroendocrine responses to an acute stressor. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 583.3.
58. 1 antagonist, CP-154,526, in the Vogel and ultrasonic vocalization (USV) tests. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 583.5.
59. Schulz, W.D., Mansbach, R.S., Sprouse, J. et al. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin-releasing factor receptors. Proc Natl Acad Sci USA 1996, 93: 10477-82.
60. Lundkvist, J., Chai, Z., Teheranian, R. et al. A nonpeptide corticotropin-releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 1996, 309: 195-200.
61. 1 receptor antagonist. Eur J Pharmacol 1997, 323: 21-6.
62. 1 receptor attenuates stress-induced relapse to drug seeking in cocaine-and heroin-trained rats. Psychopharmacology 1998, 137: 184-90.
63. Webster, E.L., Lewis, D.B., Torpy, D.J. et al. In vivo and in vitro characterization of antalarmine, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996, 137: 5747-50.
64. Hodge, C.N., Aldrich, P.E., Wasserman Z.R. et al. Corticotropin-releasing hormone receptor antagonists: Framework design and synthesis guided by ligand conformational studies. J Med Chem 1999, 42: 819-32.
65. 1) receptor. 26th Annu Meet Soc Neurosci (Nov 16-21, Washington, DC) 1996, Abst 609.13.
66. Chorvat, R.J., Bakthavatchalam, R., Beck, J.P. et al. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. J Med Chem 1999, 42: 833-48.
67. Beck, J.P., Arvanitis, A.G., Curry, M.A. et al. Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists. Bioorg Med Chem Lett 1999, 9: 967-72.
68. Curry, M.A., Beck, J.P., Folmer, B.K. et al. Thiazolo[4,5-d]pyrimidine thiones and -ones as potent corticotropin-releasing hormone (CRH-R1) receptor antagonists. 216th ACS Natl Meet (Aug 23-27, Boston) 1998, Abst MEDI 136.
69. Wustrow, D.J., Capiris, T., Rubin, R. et al. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg Med Chem Lett 1998, 8: 2067-70.
70. Davis, M.D., Cooke, L.W. The non-peptide CRF-R1 antagonist, PD171729, inhibits corticotropin-releasing factor (CRF)-induced norepinephrine release in the cortex of rats. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 583.2.
71. Pugsley, T., Akunne, H., Zoski, K. et al. In vitro and in vivo characterization of PD171729, a nonpeptide corticotropin-releasing factor (CRF) receptor antagonist. 28th Annu Meet Soc Neurosci (Nov 7-12, Los Angeles) 1998, Abst 234.10.
72. Wilcoxen, K., Chen, C., Huang, C. et al. Design and synthesis of NBI-30545 and analogues as potent CPF receptor antagonists. 217th ACS Natl Meet (March 21-25, Anaheim) 1999, Abst MEDI 002.
73. Gilligan, P.J., Baldauf, C., Cocuzza, A. et al. Pyrazolo-[1,5-a]-pyrimidine CRF antagonists: Synthesis and structure activity relationships. 216th ACS Natl Meet (Aug 23-27, Boston) 1998, Abst MEDI 135.
74. 1 receptor antagonists: Design, synthesis and structure activity relationships. 217th ACS Natl Meet (March 21-25, Anaheim) 1999, Abst MEDI 107.
75. Gilligan, P.J., He, L., Zaczek, R. et al. DMP696: A potent, orally bioavailable pyrazolo-[1,5-a]-s-triazine corticotropin-releasing factor (CRF) antagonist. 217th ACS Natl Meet (March 21-25, Anaheim) 1999, Abst MEDI 004.
76. 1) receptor antagonists. 217th ACS Natl Meet (March 21-25, Anaheim) 1999, Abst MEDI 003.
77. Beck, J.R., Tivitmahaisoon, R., Folmer, B.K. et al. Imidazo[4,5-c]pyrazoles: A novel heterocyclic series of corticotropin-releasing hormone (CRF-R1) antagonists. 217th ACS Natl Meet (March 21-25, Anaheim) 1999, Abst MEDI 001.
78. Beck, J.P., Folmer, B.K. Curry, M.A. et al. Imidazo[4,5-c]pyrazoles as corticotropin-releasing hormone (CRF-R1) receptor antagonists: Detailed pyrazole SAR and synthesis. 217th ACS Natl Meet (March 21-25, Anaheim) 1999, Abst MEDI 106.
79. Beck, J.R., Bakthavatchalam, R., Curry, M.A. et al. N-Aryl aminotriazolopyrimidines as corticotropin-releasing hormone (CRH-R1) antagonists. 215th ACS Natl Meet (March 29-April 2, Dallas) 1998, Abst MEDI 140.
80. Rajagopalan, R., Junnier, M.L., Chorvat, R.J. et al. Aryloxytriazolopyridines and -pyrimidines: Potent corticotropin-releasing hormone receptor (CRH1) antagonists. Synthesis and SAR. 215th ACS Natl Meet (March 29-April 2, Dallas) 1998, Abst MEDI 142.
81. Bakthavatchalam, R., Arnold, C.R., Arvanitis, A.G. N-Aryl aminotriazolopyrimidines and -pyridines: Synthesis and evaluation as selective corticotropin-releasing hormone (CRH1) receptor antagonists. 215th ACS Natl Meet (March 29-April 2, Dallas) 1998, Abst MEDI 143.
82. Arvanitis, A.G., Bakthavatchalam, R., Beck, J.P. et al. Aryland anilino-triazolopyridines as corticotropin-releasing factor (CRF) receptor antagonists. 215th ACS Natl Meet (March 29-April 2, Dallas) 1998, Abst MEDI 144.